Filed Pursuant to
Rule 424(b)(3)
Registration
No. 333-265953
PROSPECTUS
SUPPLEMENT NO. 75
(to
Prospectus dated August 5, 2022)

MSP
RECOVERY, INC.
Up
to 909,982 Shares of Class A Common Stock
Up
to 755,200,000 Warrants to Purchase Shares of Class A Common Stock
Up
to 236,019 Shares of Class A Common Stock Underlying Warrants
This
prospectus supplement no. 75 amends and supplements the prospectus dated August 5, 2022 (as supplemented or amended from time to time,
the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-265953). This prospectus supplement
is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form
8-K, filed with the Securities and Exchange Commission (the “SEC”) on August 31, 2026 (the “Current Report”).
Accordingly, we have attached the Current Report to this prospectus supplement.
This
prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the “Selling
Securityholders”), or their permitted transferees, of up to 909,982 shares of our Class A Common Stock, par value $0.0001 per share
(the “Class A Common Stock”) issued or issuable to certain Selling Securityholders (the “Total Resale Shares”),
as follows:
| ● | up
to 172,692 shares of Class A Common Stock issued or issuable to the Selling Securityholders,
including the Sponsor (as defined below), upon the exercise of up to 325,000 Private Warrants
(as defined below) and up to 755,200,000 New Warrants (as defined below), and the resale
from time to time of such New Warrants. The Private Warrants were originally included in
the Private Units (as defined below) issued in a private placement simultaneously with the
Company. |
| ● | up
to 1,315 shares of Common Stock issued to certain Selling Securityholders, including the
Sponsor, in connection with the Business Combination (as defined below) upon conversion of
the Founder Shares (as defined below). The Founder Shares were originally issued at a price
of $21.875 per share. |
| ● | up
to 149 shares of Class A Common Stock included in the Private Units, which were originally
issued to certain Selling Securityholders, including the Sponsor, together with the Private
Warrants at a price of $1,750.00 per unit. |
| ● | up
to 724,107 shares of Class A Common Stock exchangeable for Up-C Units originally issued to
certain Selling Securityholders, including the Members (as defined below), as consideration
in the Business Combination for their membership interests in the MSP Purchased Companies
(as defined below) or issuable pursuant to the terms of existing contracts. |
| ● | up
to 11,434 shares of Class A Common Stock issued to certain Selling Securityholders upon exchange
of Up-C Units designated by the Members and issued in a private placement by the Company
in lieu of a corresponding number of Up-C Units to which such Members were otherwise entitled
but designated back to the Company and Opco pursuant to the terms of the Business Combination.
Such Selling Securityholders paid no cash consideration for such Up-C Units or the underlying
shares of Common Stock. |
| ● | up
to 285 shares of Class A Common Stock issued to certain Selling Securityholders in a private
placement by the Company pursuant to the terms of existing contracts. Such Selling Securityholders
paid no cash consideration for such shares of Common Stock. |
In
addition, this prospectus relates to the issuance by us of up to 236,019 shares of our Class A Common Stock issuable upon exercise of
warrants as follows:
| ● | 1,036
shares of Class A Common Stock issuable upon the exercise of up to 4,532,405 Public Warrants
(as defined below), which were originally issued in the initial public offering of units
of the Company at a price of $1,750.00 per unit, with each unit consisting of one share of
Class A Common Stock and one-half of one Public Warrant. Following anti-dilution adjustments
made in connection with the Business Combination, the Public Warrants have an exercise price
of $0.4375 per share. Because the exercise price of the Public Warrants is only $0.4375 per
share, we believe holders of the Public Warrants will likely exercise their Public Warrants.
However, given the low exercise price, we would only receive nominal proceeds (less than
$500) therefrom. |
| ● | 234,983
shares of Class A Common Stock issuable upon the exercise of up to 1,028,046,326 New Warrants
(as defined below), which were originally distributed to stockholders of the Company without
charge as a dividend pursuant to the terms of the Business Combination. The New Warrants
have an exercise price of $50,312.50 per share. The exercise price of the New Warrants are
highly dependent on the price of our Class A Common Stock and the spread between the exercise
price of the New Warrants and the price of our Common Stock at the time of exercise. If the
market price for our Class A Common Stock is less than $50,312.50 per share, we believe warrant
holders will be unlikely to exercise their New Warrants. The last reported sale price of
the Class A Common Stock, as indicated below, is currently significantly below the $50,312.50
per share exercise price. There is no guarantee therefore that holders will exercise the
New Warrants, and in any event, even if holders exercise New Warrants, we will not retain
any proceeds from the exercise of the New Warrants, as described below. We do not expect
to rely on the cash exercise of the New Warrants to fund our operations. Instead, we intend
to rely on our primary sources of cash discussed elsewhere in this prospectus to continue
to support our operations. See “The Company and Management’s Discussion and Analysis
of Financial Condition and Results of Operations - Liquidity and Capital Resources”
for additional information. |
Our
Common Stock, Public Warrants and New Warrants are eligible for unsolicited quotations on the OTC Markets Group’s Expert Market
under the symbols “MSPR,” “MSPRZ,” and “MSPRW,” respectively. Quotations for securities on the Expert
Market are not publicly available, and our securities do not have an active public trading market. Accordingly, current closing prices
for our Common Stock, Public Warrants, and New Warrants are not publicly available.
Effective
at 11:59 PM EDT on September 1, 2025, the Company amended its Second Amended and Restated Certificate of Incorporation filed with the
Secretary of State of the State of Delaware to effect a 1-for-7 reverse stock split of the Company’s common stock (the “Reverse
Split”). Unless otherwise noted, the share and per share information in this Prospectus Supplement No. 75 have been adjusted to
give effect to the Reverse Split.
Investing
in our securities involves risks. Before you invest in our securities, please carefully read the information provided in the “Risk
Factors” section beginning on page 9 of the Prospectus and any in any applicable prospectus supplement, and Item IA of our
Annual Report on Form 10-K for the fiscal year ending December 31, 2024, filed with the SEC on April 16, 2025.
Neither
the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined
if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus supplement is August 31, 2026.
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 14, 2026
MSP
Recovery, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39445 |
|
84-4117825 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
3525
NW 7th Street
Miami, Florida | | 33125 |
| (Address
of principal executive offices) | | (Zip
Code) |
(305)
614-2222
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Class A common stock, $0.0001
par value per share |
|
MSPR |
|
OTC Market Group, Inc. |
| |
|
|
|
|
| Redeemable warrants, each
lot of 4,375 warrants exercisable for one share of Class A common stock at an exercise price of $50,312.50 per share |
|
MSPRW |
|
OTC Market Group, Inc. |
| |
|
|
|
|
| Redeemable warrants, each
lot of 4,375 warrants exercisable for one share of Class A common stock at an exercise price of $0.4375 per share |
|
MSPRZ |
|
OTC Market Group, Inc. |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement
Hazel
Partners Holdings, LLC Fundings
On
August 17, 2026, MSP Recovery, Inc. (the “Company”), through its subsidiaries, entered into a letter agreement with Hazel
Partners Holdings LLC (“Hazel”), in its capacity as administrative agent and lender under the Company’s existing working
capital credit facility (the “August 17, 2026 Letter Agreement”) to provide $0.03 million to be used primarily for operating
expenses.
On
August 26, 2026, the Company, through its subsidiaries, entered into a letter agreement with Hazel, in its capacity as administrative
agent and lender under the Company’s existing working capital credit facility (the “August 26, 2026 Letter Agreement,”
and collectively with the August 17, 2026 Letter Agreement, the “Hazel Letter Agreements”) to provide $0.03 million to be
used primarily for operating expenses.
As
previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Q3-2025
Form 10-Q”), the Company is party to a working capital credit facility with Hazel (the “Working Capital Credit Facility”),
which includes a discretionary funding mechanism referred to as the Operational Collection Floor. Advances under the Operational Collection
Floor are made solely at Hazel’s discretion, are not subject to any commitment or minimum availability, and are conditioned on
the satisfaction or waiver of applicable conditions under the governing credit documentation. The Working Capital Credit Facility does
not provide the Company with committed liquidity, does not establish a borrowing base, and does not obligate Hazel to fund any amounts.
As
of the filing of the Q3-2025 Form 10-Q, the Company disclosed that aggregate advances under the Operational Collection Floor had reached
approximately $6.0 million, and that no remaining funding capacity was available under the facility at that time.
Pursuant
to the Hazel Letter Agreements, Hazel has agreed, in its sole discretion, to make two one-time advances of $0.03 million and $0.03 million
(the “Advances”), respectively, to increase the Operational Collection Floor beyond the previously disclosed level. The advances
were funded on August 18, 2026 and August 28, 2026, respectively, subject to the conditions set forth in the Hazel Letter Agreements
and the underlying credit agreement, including the absence of any event of default or default at the time of funding.
The
Advances are standalone accommodations, and do not reinstate, replenish, or otherwise reopen availability under the Working Capital Credit
Facility or the Operational Collection Floor. Other than these specific advances, no additional funding is currently available to the
Company under the Working Capital Credit Facility, and the Company has no rights to, and no reasonable basis to expect, any further advances
thereunder. The Hazel Letter Agreements do not modify the discretionary nature of the facility, do not create any commitment for future
funding, and do not provide the Company with access to ongoing or recurring liquidity.
The
Company cautions that the receipt of the Advances should not be viewed as indicative of Hazel’s willingness to provide future funding,
the availability of additional liquidity, or the Company’s ability to meet its operating or debt service obligations beyond the
funding of this specific amount.
The
foregoing description of the Hazel Letter Agreements does not purport to be complete and are qualified in their entirety by reference
to the Hazel Letter Agreements, copies of which are filed as exhibits to this Current Report on Form 8-K.
VRM
MSP Recovery Partners, LLC Advances
On
August 14, 2026, the Company entered into a letter agreement (the “Third Addendum”) with VRM MSP Recovery Partners, LLC (“VRM”),
pursuant to which VRM agreed to make available a one-time advance of recovery proceeds of $0.03 million. The Third Addendum serves as
an addendum to the letter agreement dated July 8, 2026, and all terms contained therein remain in full force and effect unless otherwise
specifically stated in the Third Addendum.
On
August 27, 2026, the Company entered into a letter agreement (the “Fourth Addendum,” and with the Third Addendum, the “VRM
Addenda”) with VRM, pursuant to which VRM agreed to make available a one-time advance of recovery proceeds of $0.03 million. The
Fourth Addendum serves as an addendum to the letter agreement dated July 8, 2026, and all terms contained therein remain in full force
and effect unless otherwise specifically stated in the Fourth Addendum.
The
Third Addendum was funded on August 14, 2026 and the Fourth Addendum was funded August 28, 2026. The advances described in the VRM Addenda
are one-time advances to be used only for operational expenses, and do not imply any obligation of VRM to provide any further advances.
VRM reserved all rights under the applicable limited liability company agreement and related documents.
The
foregoing descriptions of the VRM Addenda do not purport to be complete, and are qualified in their entirety by reference to the full
text of the VRM Addenda, which are filed as exhibits to this Current Report on Form 8-K.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
To
the extent required by Item 2.03 of Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K is incorporated
herein by reference.
Item
9.01. Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
| 10.1 |
|
Hazel Letter Agreement dated August 17, 2026 |
| 10.2 |
|
Hazel Letter Agreement dated August 26, 2026 |
| 10.3 |
|
Amendment No. 3 to Second Amended and Restated Credit Agreement dated October 2, 2024 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on October 7, 2024) |
| 10.4 |
|
Virage Letter Agreement dated August 14, 2026 |
| 10.5 |
|
Virage Letter Agreement dated August 27, 2026 |
| 104 |
|
Cover Page Interactive File (the cover page tags are
embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
MSP Recovery, Inc. |
| Dated: August
31, 2026 |
|
| |
By: |
/s/
Thomas Hawkins |
| |
Name: |
Thomas Hawkins |
| |
Title: |
Director and Member
of the Special Committee |